Oxcarbazepine (Epilepsy)

Neonatal medical care

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8084
R24702		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Neonatal intensive care unit (NICU) throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.83 [0.05;13.63] C
excluded (control group) 		1/4   2/7 3 4
ref
S8075
R24642		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Neonatal intensive care unit (NICU) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 3.33 [0.23;49.10] C 1/4   2/22 3 4
ref
S5927
R15094		 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 Admission to neonatal care unit 3rd trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.59 [0.35;1.01] C
excluded (control group) 		46/465   24/154 70 465
ref
S5910
R14892		 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 Admission to neonatal care unit 3rd trimester population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.33 [0.98;1.82]
excluded (control group) 		46/465   49,612/689,482 49,658 465
ref
S5918
R14988		 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Admission to neonatal care unit 3rd trimester population based cohort retrospective unexposed, sick Adjustment: Yes 1.04 [0.73;1.49] 46/465   152/1,708 198 465
ref
S6171
R16240		 Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 Admission to a neonatal unit throughout pregnancy prospective cohort unexposed, disease free Adjustment: No 37.81 [1.54;928.50] C 2/2   1,822/24,778 1,824 2
ref
Total 3 studies 3.13 [0.43;22.52] 2,025 471
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 1 3.33[0.23; 49.10]3427%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Oxcarbazepine) (Controls unexposed, sick), 2013Artama, 2013 2 1.04[0.73; 1.49]19846551%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006Viinikainen, 2006 3 37.81[1.54; 928.50]1,824222%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 63% 3.13[0.43; 22.52]2,0254710.5100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed, sick; 3: Oxcarbazepine) (Controls unexposed, disease free) ;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.13[0.43; 22.52]2,02547163%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 37.81[1.54; 928.50]1,8242 -NAViinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 1 unexposed, sickunexposed, sick 1.06[0.75; 1.51]2014690%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 Tags Adjustment   - No  - No 9.55[0.90; 101.06]1,827623%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 2   - Yes  - Yes 1.04[0.73; 1.49]198465 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 All studiesAll studies 3.13[0.43; 22.52]2,02547163%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 30.5100.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 5927, 5910, 8084

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 4.78[0.20; 115.83]51,48246776%NAArtama (Oxcarbazepine) (Controls unexposed, disease free), 2013 Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 2 unexposed, sick controlsunexposed, sick controls 1.06[0.75; 1.51]2014690%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.60[0.36; 1.01]734690%NAAydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 20.510.01.0